Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture & Organoids 2019

Kenneth Brouwer's Biography

Kenneth Brouwer, Vice President of Technology and ADME-TOX, BioIVT

Dr. Brouwer is Vice President of Technology, ADME-Tox at BioIVT, which provides solutions to address questions that arise during drug discovery and development in the areas of hepatic drug transport, metabolism, drug interactions, transport and metabolism regulation and hepatotoxicity. Dr. Brouwer has an ongoing interest in the metabolic disease state area and in the NAFLD/NASH area in particular, with recent publications detailing the importance of the adaptive response in the liver to increased intracellular concentrations of bile acids, and the utility of in vitro biomarkers to predict in vivo effects.

Prior to this, Dr. Brouwer served as the Chief Scientific Officer at Qualyst Transporter Solutions, and as Executive Director, at PPD Discovery, where he led the scientific and administrative operations within the preclinical groups. Before joining PPD Discovery, he started the Clinical PK group (Glaxo) and later served as Director, Preclinical Development, at GlaxoSmithKline. He was responsible for the DMPK issues leading to candidate selection, review of candidate project plans, and the transition from candidate selection to full development. Dr. Brouwer has lead and directed large international multidisciplinary project teams and presented at FDA panel reviews.

Dr. Brouwer has over 80 publications in peer reviewed journals and is the holder of 3 patents. Dr. Brouwer serves on the Editorial Advisory Board for the Journal of Pharmaceutical Sciences and the Applied In Vitro Toxicology journal and is a reviewer for several additional journals. Dr. Brouwer is an adjunct faculty member in the Division of Molecular Pharmaceutics at the School of Pharmacy, University of North Carolina.

Kenneth Brouwer Image

The Use of Organotypic Liver Co-cultures for Use in Disease Modeling and Drug Development

Tuesday, 15 October 2019 at 13:00

Add to Calendar ▼2019-10-15 13:00:002019-10-15 14:00:00Europe/LondonThe Use of Organotypic Liver Co-cultures for Use in Disease Modeling and Drug Development3D-Culture and Organoids 2019 in Coronado Island, CaliforniaCoronado Island,

As the discovery and development of anti-fibrotic therapies still rely heavily on animal models, there remains an opportunity for robust and relevant in vitro models to support the identification and preclinical evaluation of potential new anti-fibrotic drugs. To this end, BioIVT has developed and characterized several human liver models which help to answer these questions.  The HEPATOPAC® micropatterned hepatocyte co-culture and the 3D ORGANDOTTM systems allow for the investigation of questions with increasing complexity and experimental duration.  In each case the incorporation of liver non-parenchymal fractions and extended culture time allow for better prediction of drug metabolism and disposition as well as disease model related endpoints.  For the ORGANDOT system, the inclusion of both Kupffer and stellate cells support the fibrotic phenotypic changes induced with TGFß1 treatment providing an in vitro model for anti-fibrotic drug efficacy.  We will report on data which demonstrates the broad utility in adding cellular and structural complexity to hepatocyte cultures as well as the optimization of endpoints including, molecular and immunohistochemical markers for the study of anti-fibrotic therapies.

Add to Calendar ▼2019-10-14 00:00:002019-10-15 00:00:00Europe/London3D-Culture and Organoids 20193D-Culture and Organoids 2019 in Coronado Island, CaliforniaCoronado Island,